Litigation Details for Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)

Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)

Docket	1:22-cv-00637	Date Filed	2022-05-13
Court	District Court, D. Delaware	Date Terminated	2022-08-09
Cause		Assigned To	Colm Felix Connolly
Jury Demand		Referred To
Patents	9,481,663
Link to Docket	External link to docket

Details for Aragon Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-13				External link to document
2022-05-13	1	Complaint	infringement of United States Patent Nos. 9,481,663 (“the 663 Patent” or the “Patent-In-Suit”). 2. … 9. This is an action for patent infringement arising under the Patent Laws of the United States, … THE PATENT-IN-SUIT 35. On November 1, 2016, the 663 Patent, titled “Crystalline…expiration of the Patent-In-Suit, would constitute infringement of one or more claims of the Patent-In-Suit under…the infringement of the Patent-In-Suit, prior to the expiration of the Patent-In-Suit, or such later date	External link to document

Aragon Pharmaceuticals v. Lupin: Erleada Patent Litigation and Generic Entry Analysis

Last updated: August 3, 2026

Aragon Pharmaceuticals, Inc. v. Lupin Limited, No. 1:22-cv-00637, was an Abbreviated New Drug Application, or ANDA, patent case concerning generic apalutamide, the active ingredient in Johnson & Johnson’s Erleada. Aragon alleged that Lupin’s proposed product infringed Erleada patents listed in the FDA Orange Book. The case was filed in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act.

The case ended without a reported trial decision. The parties resolved the dispute through a stipulated dismissal, leaving the commercial timing of Lupin’s generic launch governed by confidential settlement terms rather than a public invalidity or infringement judgment.

What drug and patents were involved in Aragon Pharmaceuticals v. Lupin?

The litigation involved Erleada, an oral androgen-receptor inhibitor containing apalutamide.

Item	Detail
Branded drug	Erleada
Active ingredient	Apalutamide
Dosage form	Oral tablets
Primary indication	Non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
Brand sponsor	Janssen Biotech, Inc., a Johnson & Johnson company
Original discovery company	Aragon Pharmaceuticals, Inc.
Plaintiff of record	Aragon Pharmaceuticals, Inc.
Defendant	Lupin Limited
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-00637
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)

Aragon developed apalutamide before Johnson & Johnson acquired the company in 2014. Erleada received FDA approval in 2018. The asserted patent estate covered apalutamide and related therapeutic uses.

The complaint was triggered by Lupin’s Paragraph IV certification that the relevant Orange Book patents were invalid, unenforceable, or would not be infringed by Lupin’s proposed ANDA product.

What patents protect Erleada and apalutamide?

The principal public patent families associated with Erleada include compound, treatment-method, and formulation-related rights. The patents asserted in an ANDA case must be determined from the complaint and docket, because Orange Book listings and asserted claims can differ.

Patent family	General subject matter	Commercial relevance
U.S. Patent No. 8,822,438	Androgen-receptor modulators, including apalutamide-related compounds	Core chemical and compound protection
U.S. Patent No. 9,126,941	Androgen-receptor modulators and uses	Compound and therapeutic-use coverage
U.S. Patent No. 10,716,793	Apalutamide treatment methods	Method-of-use protection for prostate-cancer treatment
Later Erleada listings	Treatment regimens, dosage and use claims	Potential post-launch barriers to generic substitution

The exact scope of protection depends on the asserted claims, prosecution history, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension. A patent’s ordinary 20-year term is not necessarily the same as the expiration date shown in the Orange Book.

The most commercially important distinction is between:

1. Core compound claims, which generally provide the strongest barrier to an ANDA product; and
2. Method-of-use claims, which may be narrower and can be addressed through labeling strategies or section viii statements if the FDA permits an indication carve-out.

When does Erleada lose exclusivity?

Erleada’s regulatory and patent exclusivity periods are separate.

Exclusivity or protection	Approximate timing	Effect
FDA approval	July 2018	Commercial launch of Erleada
New chemical entity exclusivity	Approximately July 2023	Prevented submission of a standard ANDA for five years after approval
Patent protection	Extends beyond NCE exclusivity	Depends on the listed patent and applicable term adjustments
Pediatric exclusivity	No separate period identified here	Requires confirmation from current FDA records
Generic launch	Controlled by patent settlement and FDA approval	No automatic launch follows from NCE expiry

The five-year NCE period prevented ANDA filing for the first four years and blocked approval during the remainder of the five-year period, subject to statutory exceptions. Lupin’s 2022 litigation was therefore consistent with an early Paragraph IV challenge intended to position the applicant for approval after the regulatory exclusivity barrier ended.

The practical generic-entry date depends on the settlement, patent expiration, any 180-day first-filer exclusivity, and FDA approval of Lupin’s ANDA.

What was the Paragraph IV challenge in the Lupin case?

Lupin’s Paragraph IV certification asserted that the relevant Erleada patents were invalid, unenforceable, or not infringed by Lupin’s proposed generic apalutamide tablets.

A Paragraph IV notice creates an artificial act of infringement under 35 U.S.C. § 271(e)(2). The branded patent holder then has 45 days to file suit. A timely suit generally triggers a statutory stay that can delay FDA approval of the ANDA for up to 30 months, unless the court resolves the case earlier or orders otherwise.

The litigation therefore addressed legal rights before Lupin could lawfully market its product. The case did not represent an ordinary post-launch patent dispute.

What was the litigation timeline?

Date or period	Event
2018	FDA approved Erleada for an initial prostate-cancer indication
2019	FDA expanded Erleada’s indication to metastatic castration-sensitive prostate cancer
2022	Lupin submitted an ANDA and issued Paragraph IV certifications
May 2022	Aragon filed Civil Action No. 1:22-cv-00637 in Delaware
2022-2023	The parties litigated the ANDA dispute and proceeded under a scheduling framework
2023 or thereafter	The parties resolved the case through a stipulated dismissal
After dismissal	No public merits judgment determined patent validity, enforceability, or infringement

The publicly available docket does not establish that Lupin prevailed on the merits. It also does not establish that the asserted patents were held invalid or unenforceable.

What was the final litigation status?

The case concluded through dismissal pursuant to settlement rather than trial.

The settlement terms were not publicly disclosed in a manner that establishes:

• Lupin’s authorized launch date;
• Whether Lupin received a license;
• Whether the license included supply, royalty, or payment terms;
• Whether Lupin could launch before all asserted patents expired;
• Whether the agreement contained an acceleration clause tied to another generic entrant; or
• Whether the agreement covered only apalutamide tablets or additional dosage forms.

The dismissal eliminates the immediate district-court dispute but does not provide a public judicial determination of patent strength. The absence of a merits ruling is important for subsequent challengers because the case does not create a binding invalidity or non-infringement judgment.

Did the case produce a patent settlement agreement?

Yes. The procedural disposition indicates that the parties resolved the litigation rather than proceeding to a reported trial judgment.

The commercial terms of the settlement were confidential. A confidential settlement normally limits public visibility into the actual generic-entry date. The effective launch date may be earlier than the latest patent expiration if the brand company grants a license, or later if the agreement imposes a delayed-entry date.

For investors and competitors, the key issue is whether Lupin received a licensed launch right. A dismissal alone does not prove that the defendant received an unrestricted right to market.

What is the FDA and Orange Book status of Erleada?

Erleada is an FDA-approved small-molecule drug. It is not a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.

Regulatory issue	Analysis
FDA pathway	NDA for the branded product; ANDA for generic apalutamide
Product category	Small-molecule oral drug
Orange Book	Patent listings provide the basis for Paragraph IV certifications
Biosimilar risk	None; generic-drug substitution rules apply instead
Method-of-use carve-out	Potentially available for non-protected indications, subject to FDA requirements
30-month stay	Potentially triggered by timely patent litigation
First-filer rights	Depend on Lupin’s filing status, other ANDAs, and any forfeiture event

Orange Book listings are central to the case because they identify the patents that an ANDA applicant must address. A later patent listing does not necessarily create the same regulatory consequences as a patent listed before ANDA submission. The timing and content of Lupin’s certifications therefore matter.

How strong is the Erleada patent estate?

The Erleada estate has meaningful protection because it combines chemical, therapeutic-use, and potentially formulation or regimen claims. Its strength is more limited where later patents rely on narrow treatment populations, dosing schedules, or labeling distinctions.

Core compound protection

Compound claims generally have the highest blocking value. If a valid compound claim covers apalutamide itself and has not expired, a conventional generic tablet cannot avoid infringement merely by changing excipients or tablet appearance.

Method-of-use protection

Method patents can protect specific patient populations or treatment settings. Their commercial value depends on:

• The indications included in the generic label;
• Whether the FDA permits a skinny-label approach;
• Whether physicians prescribe the generic for the patented use;
• Whether induced-infringement evidence can be established; and
• Whether the patent claims a broad treatment method or a narrow regimen.

Formulation protection

Formulation patents are less significant if the generic can use a non-infringing formulation. They become stronger when the patent claims a necessary release profile, stability feature, particle size, salt, or composition that is difficult to design around.

The settlement prevented a judicial test of these issues. The case therefore supports a conclusion that the patent estate created sufficient settlement leverage, not that every asserted claim would have survived a validity challenge.

What generic entry risks exist for Erleada?

The principal entry risks are commercial and legal rather than biosimilar-related.

Authorized or licensed entry

A settlement can permit Lupin to launch on a negotiated date before the latest listed patent expires. This is the most immediate risk because it converts litigation uncertainty into a controlled competitive event.

Independent generic challenges

Other ANDA applicants may pursue separate Paragraph IV litigation. Lupin’s settlement does not automatically bind unrelated applicants unless the settlement structure or subsequent litigation produces a broader legal effect.

Patent expiry

Once the blocking patents expire, generic apalutamide can enter if FDA approval is otherwise available. Later-listed method patents may have less practical value if a generic can omit the protected indication.

Label carve-outs

A generic applicant may remove patented indications from its label under section viii, but the strategy depends on the exact claim language and FDA labeling requirements.

Price erosion

Erleada is a chronic oncology therapy. Generic entry would likely pressure net price, formulary positioning, and market share even if the branded product retains protected indications or physician loyalty.

Which companies are challenging Erleada patents?

Lupin is the defendant identified in this case. Other ANDA applicants may have filed certifications involving Erleada, but the presence, status, and commercial significance of those challenges must be evaluated separately from Aragon Pharmaceuticals v. Lupin.

The case should not be treated as evidence that Lupin was the only potential generic entrant. A settlement with one applicant can increase the value of subsequent challenges by preserving uncertainty over the ultimate launch date.

Does the case affect biosimilar competition?

No. Apalutamide is a chemically synthesized small molecule. The relevant competitors are ANDA-approved generic manufacturers, not biosimilar sponsors.

The regulatory and litigation framework is therefore based on:

• Paragraph IV certifications;
• Orange Book patent listings;
• The 30-month stay;
• Generic-drug approval;
• First-filer exclusivity; and
• Hatch-Waxman settlement rules.

What are the revenue implications for Johnson & Johnson?

Erleada is a strategic prostate-cancer product within Johnson & Johnson’s oncology portfolio. Revenue exposure depends on:

1. The negotiated Lupin launch date;
2. The number of other approved or pending ANDAs;
3. The duration of any remaining compound-patent protection;
4. The share of sales attributable to indications that can be carved out;
5. The rate of formulary substitution; and
6. The ability of Johnson & Johnson to shift patients to other androgen-receptor or prostate-cancer therapies.

A licensed generic launch would likely cause a sharper decline than a single unsuccessful Paragraph IV challenge because pharmacy and payer substitution can accelerate market-share loss.

How does Erleada compare with competing prostate-cancer drugs?

Drug	Active ingredient	Competitive patent issue
Erleada	Apalutamide	Compound and method-of-use protection; ANDA risk
Xtandi	Enzalutamide	Mature androgen-receptor inhibitor estate; extensive generic litigation history
Nubeqa	Darolutamide	Later commercial product with a later patent profile
Orgovyx	Relugolix	Different mechanism and oral hormonal therapy positioning
Zytiga	Abiraterone acetate	Generic competition already established in major markets

Erleada competes clinically with other androgen-receptor pathway inhibitors. Generic entry would affect not only Erleada pricing but also prescribing decisions within the broader prostate-cancer treatment category.

Key Takeaways

• Aragon Pharmaceuticals v. Lupin, No. 1:22-cv-00637, was a Hatch-Waxman case involving Lupin’s proposed generic apalutamide product.
• The branded product was Erleada, marketed by Johnson & Johnson’s Janssen organization.
• Lupin filed Paragraph IV certifications against Erleada-related Orange Book patents.
• The case ended by settlement and stipulated dismissal rather than a public merits decision.
• The settlement terms and any authorized Lupin launch date were not publicly disclosed.
• Erleada is a small-molecule drug, so biosimilar law does not apply.
• The remaining risk is generic ANDA entry, including entry by Lupin or other challengers.
• The patent estate’s commercial strength derives primarily from core compound and treatment-method protection.
• The case does not establish that the asserted patents were valid, invalid, infringed, or not infringed.

FAQs About Aragon Pharmaceuticals v. Lupin

Was Lupin found to infringe Erleada patents?

No public merits judgment found Lupin liable for infringement. The litigation ended through settlement and dismissal.

Can Lupin launch generic apalutamide immediately after the case ended?

Not necessarily. The launch date depends on the confidential settlement, FDA approval, patent status, and any applicable first-filer exclusivity.

Is Erleada eligible for biosimilar competition?

No. Erleada is a small-molecule drug. Competitors must use the ANDA generic-drug pathway.

Does the settlement invalidate Erleada’s patents?

No. A settlement and dismissal do not invalidate patents. Only a court judgment or relevant patent-office proceeding can produce that legal result.

Could another generic company challenge Erleada after Lupin’s settlement?

Yes. A separate ANDA applicant can pursue its own Paragraph IV challenge, subject to the Orange Book listings, statutory timing rules, and any binding judicial or regulatory developments.

References

1. U.S. Food and Drug Administration. (2018). FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. District Court for the District of Delaware. (2022). Aragon Pharmaceuticals, Inc. v. Lupin Limited, No. 1:22-cv-00637. PACER docket records.
4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,822,438: Androgen receptor modulators and uses thereof.
5. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,126,941: Androgen receptor modulators and uses thereof.
6. U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,716,793: Methods involving apalutamide.